In some malignancies, such as multiple myeloma (MM), diffuse large B-cell lymphoma (DLBCL), Hodgkin’s lymphoma (HL), and glioblastoma multiforme (GBM), NF-κB is often constitutively activated by recurrent genetic alterations that target core components or upstream regulators of both the canonical and non-canonical NF-κB pathways. The gene discussed is NFKB1; the disease is Miyoshi myopathy.